DOCSLIB.ORG

Antibodies That Bind Integrin Alpha-V Beta-8 Integrin-Alpha-V Beta-8 Bindende Antikörper Anticorps Qui Se Lient À L’Intégrine Alpha-V Bêta-8

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antibodies That Bind Integrin Alpha-V Beta-8 Integrin-Alpha-V Beta-8 Bindende Antikörper Anticorps Qui Se Lient À L’Intégrine Alpha-V Bêta-8 (19) TZZ ¥_T (11) EP 2 744 823 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/00 (2006.01) C07K 14/705 (2006.01) 02.08.2017 Bulletin 2017/31 C07K 16/28 (2006.01) (21) Application number: 12823966.2 (86) International application number: PCT/US2012/051373 (22) Date of filing: 17.08.2012 (87) International publication number: WO 2013/026004 (21.02.2013 Gazette 2013/08) (54) ANTIBODIES THAT BIND INTEGRIN ALPHA-V BETA-8 INTEGRIN-ALPHA-V BETA-8 BINDENDE ANTIKÖRPER ANTICORPS QUI SE LIENT À L’INTÉGRINE ALPHA-V BÊTA-8 (84) Designated Contracting States: US-A1- 2009 324 604 US-A1- 2011 071 278 AL AT BE BG CH CY CZ DE DK EE ES FI FR GB US-B2- 7 087 405 GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR • CLAUS NEUROHR ET AL: "Activation of Transforming Growth Factor-[beta] by the (30) Priority: 17.08.2011 US 201161524708 P Integrin [alpha]v[beta]8 Delays Epithelial Wound 11.05.2012 US 201261646111 P Closure", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR (43) Date of publication of application: BIOLOGY, vol. 35, no. 2, 1 August 2006 25.06.2014 Bulletin 2014/26 (2006-08-01) , pages 252-259, XP055088389, ISSN: 1044-1549, DOI: (73) Proprietor: The Regents of the University of 10.1165/rcmb.2006-0013OC California • Stephanie Cambier ET AL: "Vascular Biology, Oakland, CA 94607-5200 (US) Atherosclerosis and Endothelium Biology Integrin alpha v beta 8 Mediated Activation of (72) Inventors: Transforming Growth Factor-beta by • NISHIMURA, Stephen Perivascular Astrocytes An Angiogenic Control Mill Valley, California 94941 (US) Switch", , 1 June 2005 (2005-06-01), • LOU, Jianlong XP055088666, Retrieved from the Internet: San Bruno, California 94066 (US) URL:http://download.journals.elsevierhealt • BARON, Jody Lynn h.com/pdfs/journals/0002-9440/PIIS00029440 Mill Valley, California 94941 (US) 10624972.pdf [retrieved on 2013-11-15] • MARKS, James • LARS FJELLBIRKELAND ET AL: "Integrin Kensington, California 94707 (US) [alpha]v[beta]8-Mediated Activation of Transforming Growth Factor-[beta] Inhibits (74) Representative: J A Kemp Human Airway Epithelial Proliferation in Intact 14 South Square BronchialTissue", THE AMERICAN JOURNAL OF Gray’s Inn PATHOLOGY, vol. 163, no. 2, 1 August 2003 London WC1R 5JJ (GB) (2003-08-01), pages533-542, XP055088657, ISSN: 0002-9440, DOI: 10.1016/S0002-9440(10)63681-4 (56) References cited: • MU ET AL.: ’The integrin alphavbeta8 mediates WO-A1-2010/022737 WO-A2-2011/020529 epithelial homeostasis through MT1- WO-A2-2011/103490 US-A- 5 635 601 MMP?dependent activation of TGF-betal’ J US-A1- 2004 170 630 US-A1- 2005 002 934 CELLULAR BIOLOGY vol. 157, 29 April 2002, pages 493 - 507, XP055071726 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 2 744 823 B1 Printed by Jouve, 75001 PARIS (FR) (Cont. next page) EP 2 744 823 B1 • ARAYA ET AL.: ’Integrin-Mediated Transforming Growth Factor-beta Activation Regulates Homeostasis of the Pulmonary Epithelial-Mesenchymal Trophic Unit’ AM J PATHOLOGY vol. 169, August 2008, pages 405 - 415, XP002501190 2 EP 2 744 823 B1 Description BACKGROUND OF THE INVENTION 5 [0001] The multifunctional cytokine transforming growth factor-β (TGF-β) affects immune, endothelial, epithelial, and mesenchymal cells during development and adult life in invertebrate and vertebrate species. In mammals, these functions are mediated by three widely expressed isoforms, TGF- β1, 2, and 3. All three isoforms interact with the same cell surface receptors (TGFBR2 and ALK5) and signal through the same intracellular signaling pathways, which involve either ca- nonical (i.e., SMADs) or noncanonical (i.e., MAPK, JUN, PI3K, PP2A, Rho, PAR6) signaling effectors. In the canonical 10 TGF-β signaling pathway, the signal is propagated from the TGF- β receptor via phosphorylation of cytoplasmic SMAD- 2/3, complex formation with SMAD-4, translocation of the SMAD-2/3/4 complex to the nucleus, and binding to SMAD response elements located in the promoter regions of many genes involved in the fibrogenic response. While the TGF- β isoforms have similar signaling partners, each serves distinct biological functions. The TGF- β isoforms have differences in binding affinities to TGF- β receptors, activation mechanism, signaling intensity or duration, or spatial and/or temporal 15 distribution. [0002] Knockout and conditional deletion models of TGF-β isoforms, receptors, and signaling mediators, as well as function-blocking reagents targeting all TGF- β isoforms, have revealed essential roles for TGF- β in T-cell, cardiac, lung, vascular,and palate development. Mice deficientin TGF- β1 either diein utero, owing to defects inyolk sac vasculogenesis, or survive to adulthood with severe multiorgan autoimmunity. Genetic deletion of TGF-β signaling mediator Smad2 20 reveals that it is essential in early patterning and mesodermal formation. Mice lacking Smad3 are viable and fertile, but exhibit limb malformations, immune dysregulation, colitis, colon carcinomas, and alveolar enlargement. In adult tissues, the TGF-β pathway is involved in the immune, mesenchymal, and epithelial cell interactions to maintain homeostasis in response to environmental stress. [0003] The homeostatic pathways mediated by TGF-β are perturbed in response to chronic repetitive injury. TGF-β 25 is a major profibrogenic cytokine in response to injury, delaying epithelial wound healing. TGF-β inhibits epithelial pro- liferation and migration, promotes apoptosis, and expands the mesenchymal compartment by inducing fibroblast recruit- ment, fibroblast contractility, and extracellular matrix deposition. Intratracheal transfer of adenoviral recombinant TGF- β 1 to the rodent lung dramatically increases fibroblast accumulation and expression of type I and type III collagen around airways and in the pulmonary interstitium. Neutralizing anti-TGF-β antibodies can block bleomycin or radiation-induced 30 pulmonary fibrosis. [0004] Increased TGF-β activity can play a role in fibrotic lung disease, glomerulosclerosis, and restenosis of cardiac vessels, primarily mediated by TGF-β. TGF-β1 function in humans is complex, as indicated by hereditary disorders involving either TGF-β1 itself or its signaling effectors. Mutations that increase the activity of the TGF-β pathway lead to defects in bone metabolism (ie, Camurati-Engelmann disease), in connective tissue (ie, Marfan syndrome), and in 35 aortic aneurysms (ie, Loeys-Dietz syndrome). Mutations that lead to decreased activity of the TGF- β pathway correlate with cancer. The role of TGF-β as a tumor suppressor in cancer is not straightforward, however, because TGF-β can also enhance tumor growth and metastasis. [0005] Despite the multiple essential functions of TGF-β, a single dose or short-term administration of a pan-TGF-β neutralizing antibody is well tolerated. No side effects are observed in rodents at doses that inhibit organ fibrosis or 40 carcinoma cell growth and metastasis. This treatment also effectively inhibits experimental fibrosis. Single-dose phase I/II clinical trials using neutralizing pan-TGF-β antibodies are ongoing for metastatic renal cell carcinoma, melanoma, focal segmental glomerulosclerosis, and idiopathic pulmonary fibrosis (Genzyme Corporation, available at genzyme- clinicalresearch.com). Neurohr et al discloses a murine monoclonal αvβ8-blocking antibody that significantly increases the degree of wound closure by inhibiting TGF- β activation (Am J Respir Cell Mol Biol, Vol 35, pp 252-259, 2006). 45 BRIEF SUMMARY [0006] Provided herein are antibody compositions that can be used for diagnosis and treatment of disorders associated with elevated TGF- β activity mediated by αvβ8. In some embodiments, provided is a humanized antibody that specifically 50 binds αvβ8 integrin, wherein the antibody inhibits release of active, mature TGFβ peptide, but does not significantly inhibit adhesion of latent TGF β to αvβ8 integrin on a αvβ8-expressing cell, and wherein the antibody has a heavy chain variable region of SEQ ID NO:8 and a light chain variable region of SEQ ID NO:9. [0007] The disclosure also provides an isolated antibody that specifically binds αvβ8, wherein the isolated antibody inhibits release of active, mature TGFβ peptide, but does not significantly inhibit adhesion of latent TGFβ to αvβ8 on a 55 αvβ8-expressing cell, and wherein the isolated antibody binds fixedα vβ8-expressing cells (e.g., formalin fixed). The antibody with these activities is referred to as 11E8, which term includes affinity-matured, humanized, chimeric, and labeled versions of the 11E8 antibodies, as well as αvβ8-binding fragments thereof. In some aspects of the disclosure, the isolated antibody specifically binds to an epitope on β8 that is within SEQ ID NO:1. In some aspects of the disclosure, 3 EP 2 744 823 B1 the antibody comprises the heavy chain CDRs shown in SEQ ID NO:10 (SEQ ID NOs:48, 49, and 50). In some aspects of the disclosure, the antibody comprises the light chain CDRs shown in SEQ ID NO:11 (SEQ ID NOs:51, 52, and 53). In some aspects of the disclosure, the antibody comprises the heavy chain CDRs shown in SEQ ID NO:10 and the light chain CDRs shown in SEQ ID NO:11. In some aspects of the disclosure, the antibody comprises the heavy chain variable 5 region shown in SEQ ID NO:10. In some aspects of the disclosure, the antibody comprises the light chain variable region shown in SEQ ID NO:11. In some aspects of the disclosure, the antibody comprises the heavy chain variable region shown in SEQ ID NO:10 and the light chain variable region shown in SEQ ID NO:11.
Load more

Recommended publications
  • Integrins: Roles in Cancer Development and As Treatment Targets
    British Journal of Cancer (2004) 90, 561 – 565 & 2004 Cancer Research UK All rights reserved 0007 – 0920/04 $25.00 www.bjcancer.com Minireview Integrins: roles in cancer development and as treatment targets 1 ,1,2 H Jin and J Varner* 1John and Rebecca Moores Comprehensive Cancer Center, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0912, USA; 2Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0912, USA The integrin family of cell adhesion proteins promotes the attachment and migration of cells on the surrounding extracellular matrix (ECM). Through signals transduced upon integrin ligation by ECM proteins or immunoglobulin superfamily molecules, this family of proteins plays key roles in regulating tumour growth and metastasis as well as tumour angiogenesis. Several integrins play key roles in promoting tumour angiogenesis and tumour metastasis. Antagonists of several integrins (a5b1, avb3 and avb5) are now under evaluation in clinical trials to determine their potential as therapeutics for cancer and other diseases. British Journal of Cancer (2004) 90, 561 – 565. doi:10.1038/sj.bjc.6601576 www.bjcancer.com & 2004 Cancer Research UK Keywords: angiogenesis; metastasis; apoptosis; integrin a5b1; integrin avb3 During the last 10 years, novel insights into the mechanisms sequences (e.g., integrin a4b1 recognises EILDV and REDV in that regulate cell survival as well as cell migration and invasion alternatively spliced CS-1 fibronectin). Inhibitors of integrin have led to the development of novel integrin-based therapeutics function include function-blocking monoclonal antibodies, pep- for the treatment of cancer. Several integrins play important tide antagonists and small molecule peptide mimetics matrix roles in promoting cell proliferation, migration and survival (reviewed in Hynes, 1992; Cheresh, 1993).
    [Show full text]
  • Cell Adhesion and Angiogenesis
    Cell adhesion and angiogenesis. J Bischoff J Clin Invest. 1997;99(3):373-376. https://doi.org/10.1172/JCI119168. Perspective Find the latest version: https://jci.me/119168/pdf Perspectives Series: Cell Adhesion in Vascular Biology Cell Adhesion and Angiogenesis Joyce Bischoff Department of Surgery, Children’s Hospital and Harvard Medical School, Children’s Hospital, Boston, Massachusetts 02115 Introduction and postcapillary venules (3). Thus, the formation of a new mi- Angiogenesis is the growth of new capillary blood vessels from crovessel requires a number of interactions that must be coor- preexisting capillaries and postcapillary venules. This process dinated in a spatially and temporally specified manner. These is critical for normal growth and development and in protec- adhesion events are likely mediated by endothelial cell adhe- tive responses such as wound healing and inflammation. In sion molecules and ECM molecules that provide instructions healthy adults, angiogenesis does not normally occur except in to the endothelial cells as they migrate into the perivascular certain phases of the female reproductive cycle. However, ab- space and assemble into new vessels with surrounding peri- errant angiogenesis can occur in a variety of pathologic set- cytes. tings. These include the neovascularization of solid tumors, the Cell adhesion and endothelial cell growth growth of vessels into the retina in diabetic retinopathy, and the unwanted vessel growth in chronic inflammatory diseases. Adhesion of endothelial cells to ECM and attainment of an The hypothesis that angiogenic diseases, in particular tumor appropriate cellular shape has been known for many years to growth and metastases, may be alleviated by inhibiting the an- be crucial for endothelial cell growth, differentiation, and sur- giogenic responses (1) has prompted many to investigate the vival.
    [Show full text]
  • Integrin Activity 7Β , and 3Β , 2 Β Chemoattractant-Stimulated Differential Regulation Of
    Differential Regulation of Chemoattractant-Stimulated β2, β3, and β7 Integrin Activity This information is current as Chanchal Sadhu, Boris Masinovsky and Donald E. Staunton of September 26, 2021. J Immunol 1998; 160:5622-5628; ; http://www.jimmunol.org/content/160/11/5622 Downloaded from References This article cites 24 articles, 11 of which you can access for free at: http://www.jimmunol.org/content/160/11/5622.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 26, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1998 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. b b Differential Regulation of Chemoattractant-Stimulated 2, 3, b and 7 Integrin Activity Chanchal Sadhu,1 Boris Masinovsky, and Donald E. Staunton Leukocyte adhesion to endothelium and extravasation are dynamic processes that require activation of integrins. Chemoattrac- tants such as IL-8 and FMLP are potent activators of leukocyte integrins. To compare the chemoattractant-stimulated activation a b a b a b of three integrins, 4 7, L 2, and V 3, in the same cellular context, we expressed an IL-8 receptor (IL-8RA) and FMLP receptor a b a b (FPR) in the lymphoid cell line JY.
    [Show full text]
  • Integrins As Therapeutic Targets: Successes and Cancers
    cancers Review Integrins as Therapeutic Targets: Successes and Cancers Sabine Raab-Westphal 1, John F. Marshall 2 and Simon L. Goodman 3,* 1 Translational In Vivo Pharmacology, Translational Innovation Platform Oncology, Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany; [email protected] 2 Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK; [email protected] 3 Translational and Biomarkers Research, Translational Innovation Platform Oncology, Merck KGaA, 64293 Darmstadt, Germany * Correspondence: [email protected]; Tel.: +49-6155-831931 Academic Editor: Helen M. Sheldrake Received: 22 July 2017; Accepted: 14 August 2017; Published: 23 August 2017 Abstract: Integrins are transmembrane receptors that are central to the biology of many human pathologies. Classically mediating cell-extracellular matrix and cell-cell interaction, and with an emerging role as local activators of TGFβ, they influence cancer, fibrosis, thrombosis and inflammation. Their ligand binding and some regulatory sites are extracellular and sensitive to pharmacological intervention, as proven by the clinical success of seven drugs targeting them. The six drugs on the market in 2016 generated revenues of some US$3.5 billion, mainly from inhibitors of α4-series integrins. In this review we examine the current developments in integrin therapeutics, especially in cancer, and comment on the health economic implications of these developments. Keywords: integrin; therapy; clinical trial; efficacy; health care economics 1. Introduction Integrins are heterodimeric cell-surface adhesion molecules found on all nucleated cells. They integrate processes in the intracellular compartment with the extracellular environment. The 18 α- and 8 β-subunits form 24 different heterodimers each having functional and tissue specificity (reviewed in [1,2]).
    [Show full text]
  • Detection of Osteopontin on Holstein Bull Spermatozoa, in Cauda Epididymal fluid and Testis Homogenates, and Its Potential Role in Bovine Fertilization
    REPRODUCTIONRESEARCH Detection of osteopontin on Holstein bull spermatozoa, in cauda epididymal fluid and testis homogenates, and its potential role in bovine fertilization David W Erikson, Amy L Way1, David A Chapman and Gary J Killian Department of Dairy & Animal Science, John O Almquist Research Center, The Pennsylvania State University, University Park, Pennsylvania 16802, USA and 1Department of Health Science, Lock Haven University, Clearfield Campus, Clearfield, Pennsylvania 16830, USA Correspondence should be addressed to G J Killian; Email: [email protected] Abstract Osteopontin (OPN) is a secreted extracellular matrix phosphoprotein identified in various tissues and fluids including those of the male and female reproductive tracts. OPN was previously identified as a 55 kDa high fertility marker in Holstein bull seminal plasma, produced by the ampulla and the vesicular gland. The objectives of this study were to characterize OPN on ejaculated and cauda epididymal sperm using immunofluorescence and western blot analysis, and to assess the role of sperm OPN in fertilization. Solubilized sperm membrane proteins from ejaculated and cauda epididymal sperm were separated by 1D SDS- PAGE, transferred to nitrocellulose, and probed with an antibody to bovine milk OPN. A 35 kDa protein was detected by this antibody in both ejaculated and cauda epididymal sperm membranes. Analyses also recognized OPN at 55 and 25 kDa in cauda epididymal fluid and testicular parenchyma homogenates respectively. Immunofluorescent analysis of ejaculated and cauda epididymal sperm showed OPN localization in a well-defined band in the postacrosomal region of the sperm head and also on the midpiece. Results of in vitro fertilization experiments showed that sperm treated with an antibody to OPN fertilized fewer oocytes than sperm treated with control medium while increasing incidence of polyspermy, suggesting a role of sperm-associated OPN in fertilization and a block to polyspermy.
    [Show full text]
  • Cell Adhesion Molecules Are Mediated by Photobiomodulation at 660 Nm in Diabetic Wounded Fibroblast Cells
    cells Article Cell Adhesion Molecules Are Mediated by Photobiomodulation at 660 nm in Diabetic Wounded Fibroblast Cells Nicolette N. Houreld * ID , Sandra M. Ayuk and Heidi Abrahamse ID Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, P.O. Box 17011, Doornfontein, Johannesburg 2028, South Africa; [email protected] (S.M.A.); [email protected] (H.A.) * Correspondence: [email protected]; Tel.: +27-11-559-6833 Received: 9 March 2018; Accepted: 12 April 2018; Published: 16 April 2018 Abstract: Diabetes affects extracellular matrix (ECM) metabolism, contributing to delayed wound healing and lower limb amputation. Application of light (photobiomodulation, PBM) has been shown to improve wound healing. This study aimed to evaluate the influence of PBM on cell adhesion molecules (CAMs) in diabetic wound healing. Isolated human skin fibroblasts were grouped into a diabetic wounded model. A diode laser at 660 nm with a fluence of 5 J/cm2 was used for irradiation and cells were analysed 48 h post-irradiation. Controls consisted of sham-irradiated (0 J/cm2) cells. Real-time reverse transcription (RT) quantitative polymerase chain reaction (qPCR) was used to determine the expression of CAM-related genes. Ten genes were up-regulated in diabetic wounded cells, while 25 genes were down-regulated. Genes were related to transmembrane molecules, cell–cell adhesion, and cell–matrix adhesion, and also included genes related to other CAM molecules. PBM at 660 nm modulated gene expression of various CAMs contributing to the increased healing seen in clinical practice. There is a need for new therapies to improve diabetic wound healing.
    [Show full text]
  • Vascular Density and Endothelial Cell Expression of Integrin Alpha V Beta
    Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours Johanne Seguin, 1 Céline Nicolazzi, 1 Nathalie Mignet, Daniel Scherman and Guy G. Chabot* Paris Descartes University; Faculty of Pharmacy; INSERM U1022; CNRS UMR8151; Chimie ParisTech; Sorbonne Paris Cité; Chemical, Genetic and Imaging Pharmacology Laboratory, F-75006 Paris, France 1 Both considered as first author because they contributed equally to this study. * Corresponding author: Guy G. Chabot, Faculty of Pharmacy, Paris Descartes University, Chemical, Genetic & Imaging Pharmacology Laboratory (INSERM U1022 - CNRS UMR 8151), 4 avenue de l’Observatoire, Paris, F-75006 France. Email: [email protected] tel. +33 1 53 73 95 59; Fax. +33 1 43 26 69 18 Authors Email addresses: J. Seguin: [email protected] ; C. Nicolazzi: [email protected] Nathalie Mignet : [email protected] D. Scherman: [email protected] ; G.G. Chabot: [email protected] Keywords: mouse tumours; vascularization; integrin alpha v beta 3; E-selectin; melanoma; colon; mammary; pancreas; sarcoma; lung Abbreviation used: CAM, endothelial cell adhesion molecule. 1 Abstract The endothelial cell adhesion molecules, including the integrin alpha v beta 3 (αvβ3) and E-selectin, are involved in the process of angiogenesis required for tumour growth, cell migration and metastasis. The purpose of this study was to assess and compare widely used tumour models to select the ones most suitable for angiogenesis research. Fifteen murine tumours were selected including melanoma (B16), colon (C26, C38, C51), mammary (MA13, MA16, MA16/Adr, MA17, MA17/Adr, MA25, MA44), pancreatic (PO2, PO3), Glasgow osteogenic sarcoma (GOS) and Lewis lung carcinoma (LLC).
    [Show full text]
  • 1 Integrin Αvβ8 on T Cells Is Responsible for Suppression of Anti
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.14.084913; this version posted May 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Integrin avβ8 on T cells is responsible for suppression of anti-tumor immunity in multiple syngeneic models and is a promising target for tumor immunotherapy Authors: Eswari Dodagatta-Marri1*, Hsiao-Yen Ma2*, Benjia Liang2,3, John Li2, Dominique S. Meyer1, Kai-Hui Sun2, Xin Ren2, Bahar Zivak4, Michael D. Rosenblum4, Mark B. Headley5, Lauren Pinzas1, Nilgun I. Reed2, Joselyn S. Del Cid2, Maeva Adoumie1, Byron C. Hann1, Sharon Yang6, Anand Giddabasappa7, Kavon Noorbehesht7, Bing Yang7, Joseph Dal Porto8, Tatsuya Tsukui2, Kyle Niessen8#, Amha Atakilit2#, Rosemary J. Akhurst1,9#@, and Dean Sheppard2#@† *These authors contributed equally to this work as first authors #These authors contributed equally as senior authors @co-corresponding authors † Lead Contact Corresponding Authors: Dean Sheppard Lung Biology Center, University of California, San Francisco 1550 4th Street, Mission Bay San Francisco, CA, 94143, USA Phone: (415) 514-4269 Fax: (415) 514-4278 e-mail correspondences to: [email protected] Rosemary J. Akhurst Helen Diller Family Comprehensive Cancer Center and Department of Anatomy, 1450 3rd Street, Mission Bay San Francisco, CA 94158-9001, USA e-mail correspondences to: [email protected]
    [Show full text]
  • Β6 Integrinosis: a New Lethal Autosomal Recessive ITGB6
    PostScript LETTER neutropenia occurred due to consumption mediating cell-cell and cell-extracellular of neutrophils during the prolonged diar- matrix interactions. Further SNPs fitting Gut: first published as 10.1136/gutjnl-2019-319015 on 14 June 2019. Downloaded from 6 integrinosis: a new lethal rhoea. Eventually, he developed cholestatic to autosomal-recessive inheritance were β hepatopathy and thrombocytopenia and improbable candidates due to lacking autosomal recessive ITGB6 died of uncontrollable GI, dermal haem- phenotype conformity (DSG4C1568T)3 orrhages and hepatic failure at 7 months or relatively high population frequency disorder leading to impaired 4 5 conformational transitions of of age. Extensive diagnostics included (TTC3G2771A). Next, we analysed the biopsies of liver, muscle, bone marrow, relevance of ITGB6V438M by structural the αVβ6 integrin receptor small intestine, the exclusion of known simulation, cell-based interaction studies, congenital diarrhoea reasons and immu- immunohistochemistry and ITGB6 knock- down in zebrafish. Anti-α β6 mono- We read with interest the recent work by nodeficiencies by leucocyte FACS, CD40L V clonal immunohistochemistry revealed Schleier et al1 demonstrating consequences expression, WASP staining, et cetera with 2 diminished intestinal α β6,6 7 which of impaired α4β7 integrin-dependent gut no results. Familial anamnesis revealed V correlated with enriched LTBP1, possibly homing of intestinal macrophages on similar fatalities of a sister and further cousins from the patient’s known gener- influencing TGF-β1 activation from its wound healing, which fits well with own 8 observations we have made in a case of ation within their first year of life due to latent precursor (figure 1B). Evolu- congenital infantile intractable diarrhoea intractable diarrhoea (figure 1A; 5 fatali- tionary ITGB6V438 conservation within linked to impaired integrin receptors in ties/16 infants).
    [Show full text]
  • Doctoral Thesis
    Doctoral thesis submitted in partial fulfilment of the requirements for the academic degree “Doctor of Philosophy (PhD)” Integrin alpha V and alpha 5 diversely regulate proliferation and adipogenic differentiation of human adipose derived stem cells. Innsbruck, December 2016 Department of Plastic, Reconstructive and Aesthetic Surgery Dissertation committee, support and supervision: Prof. Dr. med. Gerhard Pierer, Prof. Dr. Günther Lepperdinger, Dr. Christian Ploner, PhD submitted by: Dr. med. univ. Evi M. Morandi 1 This work was written and submitted by Dr. med. univ. Evi M. Morandi Andreas Hofer Str. 26 6020 Innsbruck, Austria Supervisor: Dr. Christian Ploner, PhD The original paper containing this work has been accepted for publication in the open access online journal Scientific Reports on 09.06.2016 and was published on 01.07.2016: ITGAV and ITGA5 diversely regulate proliferation and adipogenic differentiation of human adipose derived stem cells. Morandi EM, Verstappen R, Zwierzina ME, Geley S, Pierer G, Ploner C. Sci Rep. 2016 Jul 1;6:28889. Innsbruck, December 2016 2 To my husband. 3 Table of contents 1. Introduction .........................................................................................................................6 1.1. Integrins, the niche and their physiologic significance in tissue engineering .........................6 1.2. Integrin signaling and relevant intracellular pathways ..........................................................7 1.3. Integrins and disease ............................................................................................................9
    [Show full text]
  • Expression of the <Alpha>6 Integrin Confers Papillomavirus Binding
    Virology 261, 271–279 (1999) Article ID viro.1999.9825, available online at http://www.idealibrary.com on View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Expression of the a6 Integrin Confers Papillomavirus Binding upon Receptor-Negative B-Cells Nigel A. J. McMillan,*,1 Elizabeth Payne,* Ian H. Frazer,* and Magnus Evander† *Centre for Immunology and Cancer Research, Department of Medicine, University of Queensland, Brisbane, Australia; and †Department of Virology, Umeå University, Umeå, Sweden Received March 26, 1999; returned to author for revision April 27, 1999; accepted May 26, 1999 Papillomaviruses (PV) bind to a wide range of cell lines in a specific and saturable manner. We have recently identified a candidate receptor for papillomavirus as the a6 integrin (Evander et al., J. Virol. 71, 2449–2456, 1997). We have further investigated the role the a6 integrin plays in PV binding. Here we show that the cells expressing the a6 integrin, partnered with either the b4 integrin or the b1 integrin, are equally able to bind PV HPV6b L1 virus-like particles, indicating that the beta partner does not play a major role in virus binding. In order to provide definitive evidence that the a6 integrin is required for PV binding we undertook to genetically complement the receptor-negative B-cell line DG75 by expressing the human a6A gene. The transduction of the a6 integrin gene into DG75 cells results in the cell surface expression of the a6 protein and this expression confers upon DG75 cells the ability to bind laminin, a normal ligand for a6 integrin.
    [Show full text]
  • Syndecan-1 Couples the Insulin-Like Growth Factor-1 Receptor to Inside-Out Integrin Activation
    3796 Research Article Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation DeannaLee M. Beauvais and Alan C. Rapraeger* Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, 1111 Highland Avenue, Madison, WI 53705, USA *Author for correspondence ([email protected]) Accepted 28 July 2010 Journal of Cell Science 123, 3796-3807 © 2010. Published by The Company of Biologists Ltd doi:10.1242/jcs.067645 Summary Syndecan-1 (Sdc1) engages and activates the avb3 (and/or avb5) integrin when clustered in human carcinoma and endothelial cells. Although the engagement is extracellular, the activation mechanism is cytoplasmic. This talin-dependent, inside-out signaling pathway is activated downstream of the insulin-like growth factor-1 receptor (IGF1R), whose kinase activity is triggered by Sdc1 clustering. In vitro binding assays using purified receptors suggest that association of the Sdc1 ectodomain with the integrin provides a ‘docking face’ for IGF1R. IGF1R docking and activation of the associated integrin is blocked by synstatin (SSTN92–119), a peptide derived from the integrin engagement site in Sdc1. IGF1R colocalizes with avb3 integrin and Sdc1 in focal contacts, but fails to associate with or activate the integrin in cells either lacking Sdc1 or expressing Sdc1D67–121, a mutant that is unable to form the Sdc1–integrin–IGF1R ternary complex. Integrin activation is also blocked by IGF1R inhibitors or by silencing IGF1R or talin expression with small- interfering RNAs (siRNAs). In both cases, expression of the constitutively active talin F23 head domain rescues integrin activation. We recently reported that SSTN92–119 blocks angiogenesis and impairs tumor growth in mice, therefore this Sdc1-mediated integrin regulatory mechanism might be a crucial regulator of disease processes known to rely on these integrins, including tumor cell metastasis and tumor-induced angiogenesis.
    [Show full text]